Related by context. All words. (Click for frequent words.) 89 Solid Tumors RECIST 84 RECIST Response Evaluation Criteria 82 RECIST criteria 79 RECIST 77 Solid Tumors criteria 74 Solid Tumors 73 CCyR 71 Solid Tumours 68 EBMT criteria 68 cEVR 68 evaluable patients 68 immunohistochemical staining 68 Index CDAI 68 CR CRu 68 complete cytogenetic 68 evaluable 68 cytogenetic response 67 Kaplan Meier analysis 67 pCR 67 Crohn Disease Activity 67 Scale EDSS 67 response CCyR 67 biochemical relapse 67 Follicular Lymphoma 66 Psoriasis Area 66 neoadjuvant chemotherapy 66 MCyR 66 remission CR 66 DAS# CRP 66 Rate ORR 66 CR nPR 66 ACR Pedi 66 immunohistochemical 66 recurrent glioblastoma multiforme 66 patients evaluable 66 Expanded Disability Status 65 univariate 65 gemcitabine carboplatin 65 mg BID dose 65 chlorambucil 65 Pharmacokinetic parameters 65 lymphocytosis 65 undetectable HBV DNA 65 multivariate Cox 65 PSADT 65 bortezomib refractory 65 Partial Response 65 relapsed MM 65 CDAI 65 underwent surgical resection 65 metastatic GIST 65 F FDG PET 65 breast carcinoma 65 KRAS mutations occur 65 preoperative chemotherapy 65 achieved CCyR 64 prospectively defined 64 differentiated thyroid 64 metastatic malignant 64 epithelial tumors 64 baseline LDH 64 plus dexamethasone 64 invasive aspergillosis 64 DAS# [002] 64 Folfox 64 Flu Cy 64 NMIBC 64 antibody titer 64 ertapenem 64 specific antigen PSA 64 CRp 64 partial remissions 64 annualized relapse 64 estimated GFR 64 PSA nadir 64 Cancer Incidence Mortality 64 aminotransferase ALT 63 secondary efficacy endpoint 63 follicular lymphomas 63 neoadjuvant 63 CIMZIA ™ 63 mg kg dose 63 HER2 overexpression 63 papillary renal cell carcinoma 63 ACTEMRA TM 63 PCWP 63 progression TTP 63 DAS# remission 63 biochemical recurrence 63 nodular partial response 63 Squamous 63 complete cytogenetic response 63 estimated glomerular filtration 63 FOLFIRI 63 HBeAg positive patients 63 morphometric vertebral fractures 63 Primary endpoints 63 ACR# response 63 pancreatic adenocarcinoma 63 platelet reactivity 63 REYATAZ r arm 63 PEG IFN 63 8mg/kg 63 SVR# 63 dasatinib 63 Doxil ® 63 MGd 63 Bezielle 63 ribavirin RBV 63 CIN2 + 63 HBeAg negative 63 HCV RESPOND 2 63 HBeAg seroconversion 63 Partial Responses 63 mg/m2 dose 63 MAGE A3 ASCI 63 confirmed CCyR 63 FOLFOX4 63 complete Early Virological 63 lopinavir r arm 63 aspartate aminotransferase AST 63 mRCC 63 standard chemotherapy regimen 63 alanine aminotransferase ALT 63 cytologically confirmed 63 XIENCE V PROMUS Stent 63 HGPIN 63 Scale cognitive subscale 63 Secondary endpoints include 63 surrogate endpoint 63 Histologic 62 chemoradiation therapy 62 VELCADE melphalan 62 ara C 62 peg interferon 62 CTAP# Capsules 62 viral kinetics 62 curative resection 62 Kaplan Meier method 62 Diffuse Large B 62 Cytogenetic 62 Secondary endpoints 62 % Confidence Interval 62 bronchial hyperresponsiveness 62 Ranolazine 62 HCV SPRINT 62 neoadjuvant therapy 62 renal tumors 62 corticosteroid dose 62 azacytidine 62 sustained virologic response 62 Placebo Controlled Trial 62 thymoma 62 achieved ACR# 62 #F FDG PET 62 mycophenolate mofetil 62 elevated ALT 62 FOLPI 62 huN# DM1 62 estramustine 62 FDG PET 62 Score TOS 62 alfa 2a 62 Severity MSCS score 62 PREZISTA r arm 62 haematologic 62 resected pancreatic cancer 62 Timed Walk 62 CIN3 62 T#I [002] 62 Severity Index PASI 62 Scale EDSS score 62 peripheral blood mononuclear 62 ribavirin therapy 62 cardiac dysfunction 62 Decitabine 62 Lymphocytic 62 EURIDIS 62 nonmetastatic 62 sunitinib Sutent ® 62 INCB# [003] 62 serum urate 62 ACR# responses 62 achieved sustained virologic 62 chemoradiotherapy 62 Hurthle cell 62 MADRS score 62 metastatic neuroendocrine tumors 62 FOLFOX6 62 FDG-PET/CT 62 FluCAM arm 62 definite stent thrombosis 62 SUVmax 62 locoregional recurrence 62 urothelial carcinoma 62 tolvaptan 62 familial amyloidotic polyneuropathy FAP 62 HER2 expression 62 EDSS score 62 imatinib therapy 62 5 Fluorouracil 62 Tumor Response 62 Castration Resistant Prostate Cancer 62 graft dysfunction 62 #.#ng/ml 62 ULORIC 62 complete remissions 62 fluvastatin 62 TIMP 1 62 serum HBV DNA 62 HER2 positive metastatic breast 62 immunostaining 61 relapsing multiple sclerosis 61 STRIDE PD 61 multivariate analyzes 61 virological response 61 intraobserver 61 leukemia CLL 61 aminotransferase levels 61 Thrombolysis 61 localized renal 61 galiximab 61 recurrent GBM 61 ZOLINZA 61 mucosal healing 61 K ras mutations 61 ACR# ACR# 61 ug kg 61 tipranavir ritonavir 61 SSc 61 dasatinib Sprycel ® 61 TLUS 61 splenectomized patients 61 KRAS wild 61 iniparib BSI 61 mL/min/#.# m 2 61 calculated creatinine clearance 61 log# reduction 61 microbiologically evaluable 61 composite endpoint 61 -#.# log# 61 underwent resection 61 mCRC patients 61 OGTT 61 EGFR TKI 61 MabCampath 61 ritonavir boosted 61 dimensional echocardiography 61 distant metastasis 61 Non Alcoholic Steatohepatitis 61 HBeAg negative patients 61 mcg albinterferon alfa 2b 61 cervical intraepithelial neoplasia 61 FDG uptake 61 rosuvastatin #mg 61 cancer mCRC 61 Ejection Fraction 61 CIMZIA TM 61 Y BOCS 61 NCCTG N# 61 thyroglobulin 61 Carotid Revascularization Endarterectomy vs. 61 peginterferon alfa 2a 61 Free Survival PFS 61 clinico pathological 61 histologically confirmed 61 HOMA IR 61 IL#B 61 NIHSS 61 docetaxel chemotherapy 61 macroalbuminuria 61 colorectal carcinoma 61 histological subtype 61 hyperphenylalaninemia HPA due 61 gastric adenocarcinoma 61 steroid dexamethasone 61 % CI #.#-#.# [007] 61 μmol L 61 pegylated interferon alfa 2b 61 Oral Fingolimod 61 leukemia AML 61 mg/m2/day 61 stage IIIB 61 hA# 61 hepatorenal syndrome 61 median PFS 61 abacavir lamivudine 61 logistic regression analysis 61 GSTP1 61 Angiographic 61 crizotinib PF # 61 PEGylated Fab fragment 61 adjuvant GIST 61 Advanced Renal Cell 61 log# copies mL 61 liver histology 61 Newly Diagnosed Multiple Myeloma 61 clinicopathological features 61 preoperative PSA 61 evaluable subjects 61 gemcitabine cisplatin 61 immunohistochemical analysis 61 prostate carcinoma 61 4mg/kg 61 demyelinating 61 pegylated alpha interferon 61 serum HCV RNA 61 Acute Ischemic Stroke 61 ELOXATIN 61 metastatic pancreatic 61 PSMA ADC 61 pT2 61 fluoropyrimidine 61 resectable 61 icatibant 61 IU ml 61 -#.# log# copies mL 61 nondiabetic patients 61 EUS FNA 61 Non inferiority 61 free survival PFS 61 Leukemias 61 Eur J Endocrinol 61 FOLFOX 61 interferon alfa 61 gefitinib Iressa 61 FOLPI regimen 61 serum antibody 61 severe exacerbations 61 CIMZIA TM certolizumab pegol 61 refractory NSCLC 61 vincristine doxorubicin 61 neurologic progression 61 median survivals 61 relapsed MCL 61 TACE 61 â ‰ ¥ 61 sustained virological response 61 pain palliation 61 Enzastaurin 61 advanced adenoma 61 urine cytology 60 HES CEL 60 ANCA associated 60 sarcomatoid 60 plus prednisone 60 telaprevir dosed 60 airway hyperresponsiveness 60 QTcF 60 Brief Psychiatric 60 % CI #.#-#.# [003] 60 pretreatment serum 60 Hormone Refractory Prostate Cancer 60 Papillary 60 ptau 60 hepatectomy 60 clinically localized prostate 60 undetectable HCV RNA 60 glomerular filtration 60 Natalizumab 60 rFVIIa 60 CLL SLL 60 Clinical Outcome 60 stage IIIb IV 60 postintervention 60 CANCIDAS 60 achieved sustained virological 60 bleomycin 60 follicular NHL 60 grade cervical intraepithelial 60 serum prostate 60 malignant lymphoma 60 ug dose 60 PegIFN RBV 60 BENICAR HCT 60 SLN biopsy 60 KRAS status 60 abnormal p# biomarker 60 Montgomery Åsberg Depression 60 Montgomery Asberg Depression 60 leukocyte count 60 intravesical 60 severe oral mucositis 60 FDG PET imaging 60 mg BID 60 small lymphocytic lymphoma 60 Immunohistochemical analysis 60 peg IFN 60 Hamilton Anxiety Scale 60 prostate cancer CaP 60 XIENCE V demonstrated 60 Myocardial Infarction Study 60 Randomized Phase II 60 locoregional 60 nomogram 60 Secondary efficacy endpoints 60 BENICAR 60 etiologic 60 severe neutropenia 60 adenotonsillectomy 60 serum phosphate 60 murine model 60 radical nephrectomy 60 sorafenib tablets 60 #mg QD [002] 60 TAXUS Express Stent 60 melphalan prednisone 60 HERmark 60 PRECiSE 60 Renal Cell Carcinoma 60 histologic 60 symptomatic VTE 60 superficial bladder cancer 60 BRIM2 60 radiochemotherapy 60 Randomized Phase 60 dose cohort 60 Virologic 60 mitoxantrone chemotherapy 60 estrogen receptor ER 60 multivariate logistic regression 60 histopathologic 60 serum clusterin levels 60 noninferiority 60 atypical ductal hyperplasia 60 placebo dexamethasone 60 ARB telmisartan 60 peginterferon alfa 2a #KD 60 Kaplan Meier estimates 60 atherothrombotic disease 60 Relapsed Refractory 60 debulking surgery 60 immunohistochemistry IHC 60 dexamethasone Decadron 60 hepatoma 60 tumor histology 60 CAMMS# 60 microbiological eradication 60 SPRYCEL ® 60 hepatic metastases 60 GOUT 60 CIN2 60 ABC/3TC 60 endoscopic remission 60 hepatocellular carcinomas 60 histologic subtype 60 urinary N telopeptide 60 duplex ultrasonography 60 Pegasys ® 60 Renal Cell Carcinoma RCC 60 comparator arm 60 histologically proven 60 Sustained virologic response 60 Refractory Hodgkin Lymphoma 60 pharmacodynamic PD 60 urine albumin 60 adjunctive placebo 60 transcranial Doppler ultrasound 60 invasive ductal 60 node metastases 60 Skin sterol 60 Multiple Myeloma MM 60 previously untreated follicular 60 desvenlafaxine succinate 60 operable breast cancer 60 refractory chronic lymphocytic 60 lactate dehydrogenase LDH 60 ExTRACT TIMI 60 Estrogen Receptor 60 colorectal adenoma 60 mcg QD 60 albumin excretion rate 60 Cardiopulmonary bypass 60 dosing cohort 60 keloid scarring 60 creatinine clearance 60 acute myeloid 60 xenograft models 60 adenoma recurrence 60 Adjuvant chemotherapy 60 Immunohistochemistry 60 NIH CPSI 60 neoadjuvant treatment 60 GAMMAGARD 60 Teriflunomide 60 conditional logistic regression 60 Arch Intern Med 60 doxorubicin cyclophosphamide 60 methotrexate monotherapy 60 ANOVA 60 HSCT 60 % CI #.#-#.# [005] 60 binary restenosis 60 spirometric 60 mg QD 60 serologically active patients 60 alkylating agent 60 fosbretabulin 60 heavily pretreated 60 EBUS FNA 60 renal cell carcinomas 60 Kaplan Meier 60 IMGN# 60 CP CPPS 60 erlotinib Tarceva ® 60 endometrial hyperplasia 60 Aflibercept 60 peginterferon 60 FLT3 ITD 60 Complete Response CR 59 PEGylated anti 59 AA Amyloidosis 59 cytogenetic responses 59 TRAIL R1 59 LUX Lung 59 recurrent NSCLC 59 hematopoietic cancers 59 papillary thyroid carcinoma 59 tumor necrosis 59 pimecrolimus cream 59 recurrent VTE 59 pmol L 59 CTEPH 59 HBeAg 59 metachronous 59 Index CDAI score 59 sUA 59 coinfected patients 59 EORTC 59 hemagglutination inhibition 59 Group RTOG 59 adenomatous 59 EGFR HER2 59 Rating Scale MADRS 59 mCi 59 Secondary endpoints included 59 GW# [003] 59 postoperative chemotherapy 59 cyclophosphamide methotrexate 59 thyroid carcinoma 59 cisplatin gemcitabine 59 Peg IFN 59 breast carcinomas 59 Gastrointestinal Stromal Tumors 59 GnRH agonists 59 antibody titers 59 ErbB2 positive 59 interferon ribavirin 59 Degarelix 59 trastuzumab Herceptin ® 59 aldosterone antagonist 59 randomized multicenter trial 59 detectable HCV RNA 59 nomograms 59 treatment naive genotype 59 IV NSCLC 59 metastatic renal cell carcinoma 59 IFN α 59 Median PFS 59 Pharmacokinetics PK 59 serum aminotransferase levels 59 univariate analysis 59 cinacalcet 59 eGFR 59 GnRH agonist 59 metastatic CRC 59 Subgroup analysis 59 Sipuleucel T 59 See CLINICAL PHARMACOLOGY 59 cytoreductive surgery 59 imatinib resistant 59 alteplase 59 SCr 59 ZACTIMA 59 hematologic toxicity 59 docetaxel Taxotere ® 59 systemic anaplastic large 59 carcinoid 59 Multivariate analysis 59 boosted protease inhibitor 59 cytoreduction 59 DOXIL 59 mCi kg 59 TAXUS p value 59 pertuzumab 59 amoxicillin clavulanate 59 Myelodysplastic Syndrome 59 Retreatment 59 Nephrol Dial Transplant 59 mcg kg 59 cardiac troponin T 59 dosage regimens 59 #Gy 59 castration resistant prostate cancer 59 Mean Symptom Complex 59 peginterferon alpha 59 myocardial necrosis 59 BCIRG 59 CRu 59 COPAXONE R 59 tumor regressions 59 Disease Activity 59 NSABP B 59 PASI scores 59 dosing cohorts 59 NIHSS score 59 nausea photophobia 59 Pharmacokinetic 59 SLNB 59 Pooled Analysis 59 Omacetaxine 59 oral allopurinol 59 Accelerated Partial Breast Irradiation 59 lymphovascular invasion 59 RoACTEMRA 59 colorectal liver metastases 59 adriamycin 59 unresectable tumors 59 BEXXAR Therapeutic Regimen 59 piperacillin tazobactam 59 clinicopathological 59 Invasive Breast Cancer 59 clinically meaningful improvement 59 pegylated interferon alfa 59 μg kg 59 x ULN 59 Pemetrexed 59 Common Toxicity Criteria 59 demonstrated antitumor activity 59 Renal Insufficiency 59 riociguat 59 anaplastic astrocytoma AA 59 ischemic cardiomyopathy 59 teriflunomide 59 Lp PLA 2 59 Clostridium difficile Infection 59 intermittent dosing 59 Hycamtin ® 59 esophageal carcinoma 59 nab paclitaxel 59 alanine aminotransferase 59 infliximab monotherapy 59 low dose cytarabine 59 Nilotinib 59 novel VDA molecule 59 seroprotection 59 Am J Cardiol 59 virologic responses 59 INC# 59 octreotide LAR 59 Controlled Trial 59 Zevalin R Ibritumomab 59 subanalysis 59 progesterone receptor PR 59 #mg dose [002] 59 diabetes mellitus DM 59 radiographic progression 59 malignant lesions 59 fallopian tube cancers 59 glycated hemoglobin levels 59 cisplatin resistant 59 relapsed myeloma 59 adjuvant systemic 59 upper endoscopy 59 PEGASYS ® 59 hypereosinophilic syndrome 59 efficacy evaluable 59 CYT# potent vascular disrupting 59 somatostatin analog 59 Chronic Lymphocytic Leukemia 59 azacitidine 59 plus ribavirin 59 recurrent metastatic 59 anemia hemoglobin 59 bFGF 59 Cutaneous T 59 glioblastoma multiforme GBM 59 rizatriptan 59 serum phosphorous 59 intestinal metaplasia 59 BEACOPP 59 #mg/m# [002] 59 XELOX 59 Severe Asthma 59 sensitivity specificity 59 efavirenz EFV 59 genotypic resistance 59 Multivariate logistic regression 59 nicardipine 59 lenalidomide Revlimid R 59 Complicated Skin 59 5 FU leucovorin 59 pulmonary metastases 59 PREZISTA r 59 B Cell Lymphoma 59 endometrial carcinoma 59 epithelial ovarian 59 carotid stenosis 59 B7 H3 59 DAS# scores 59 squamous histology 59 clinicopathologic 59 carcinoid tumors 59 KRAS mutations 59 MACCE 59 plasma uric acid 59 posaconazole 59 erythrocyte sedimentation rate 59 log# IU mL 59 Adjuvant Treatment 59 antibody MAb 59 p = #.# [003] 59 angiographic outcomes 59 HER2 positive cancers 59 LV dysfunction 59 Risk Stratification 59 febrile neutropenia 59 paclitaxel cisplatin 59 moderate renal impairment 59 ASCUS 59 sirolimus stent 59 virologic response 59 Cholinesterase Inhibitors 59 logistic regression models 59 Clinical Practice Guideline 59 histopathologic examination 59 dacarbazine 59 troponin T 59 Naive Patients 59 mucinous 59 transurethral resection 59 statistical significance p 59 serum concentrations 59 tumor xenograft models 59 hemoglobin A1c levels 59 sipuleucel T 58 assessing T DM1 58 cTnI 58 elevated serum creatinine 58 pericardial effusion 58 Soft Tissue Sarcoma 58 relapsed multiple myeloma 58 mITT population 58 antithymocyte globulin 58 recurrent glioma 58 Immunohistochemical staining 58 Xelox 58 tipranavir r 58 hypophosphatemia 58 rapid virologic response 58 EGFR expressing mCRC 58 PegIFN 58 prior chemotherapy regimens 58 nodal metastasis 58 Her2/neu 58 Surgical resection 58 APPRAISE 58 ERalpha 58 intratumoral injection 58 Prostate AdenoCarcinoma Treatment 58 ALT flares 58 Antigen Specific 58 Gynecologic Oncology Group 58 myelofibrosis polycythemia vera 58 lymph node metastases 58 multigene expression test 58 bendamustine 58 intravascular hemolysis 58 Clusterin 58 oxycodone CR 58 BMI ≥ 58 fallopian tube carcinoma 58 Radiation Therapy Oncology 58 doxorubicin HCl liposome injection 58 prognostic indicator 58 Ceplene/IL-2 58 histological subtypes 58 Poisson regression 58 transgene expression 58 imatinib Gleevec ® 58 PEGylated interferon beta 1a 58 NATRECOR R 58 iPTH 58 HER2 negative 58 pretest probability 58 univariate analyzes 58 Hemodialysis Patients 58 orthotopic model 58 Autologous Stem Cell Transplantation 58 lymph node metastasis 58 RE LY ® 58 Capacity FVC 58 Hepatotoxicity 58 Immunohistochemical 58 seropositivity 58 multivariable analysis 58 dacarbazine DTIC 58 oral FTY# 58 fluorouracil 58 irbesartan 58 Philadelphia Chromosome Positive 58 tumor shrinkage 58 Relapsing Multiple Sclerosis 58 Ph + ALL 58 multiple logistic regression 58 mcg BID 58 chemoradiation 58 System IPSS 58 null responders 58 visceral metastases 58 fludarabine cyclophosphamide 58 Mg Uk 58 Etanercept 58 liposome injection 58 bevacizumab Avastin ® 58 q8h 58 daunorubicin 58 selective modulator 58 leiomyomas 58 Hb A1C 58 Stage IIB 58 J Am Coll 58 salmeterol fluticasone propionate 58 androgen suppression 58 Irinotecan 58 posttreatment 58 heavily pretreated patients 58 hemagglutination inhibition HAI 58 TNF Tumor Necrosis Factor 58 nephrectomy 58 Kaplan Meier estimate 58 iodixanol 58 tumor progression TTP 58 intact parathyroid hormone 58 #mg/day [001] 58 liver transplant recipients 58 stage IIIA 58 hepatitis C genotype 58 ELACYT 58 NYHA functional class 58 achieved PASI 58 axillary lymph node 58 achieve sustained virologic 58 dose dexamethasone 58 pegylated interferon alpha 58 locoregional disease 58 generalized edema 58 DAPT 58 antiangiogenic therapy 58 Logistic regression 58 intravenous bolus 58 epithelial ovarian cancer 58 CDAI score 58 LEXIVA r 58 adalimumab 58 IgG antibody 58 Ann Oncol 58 multivariate regression analysis 58 mcg mL 58 DFMO 58 EBRT 58 T1a 58 follicular lymphoma FL 58 Neoadjuvant 58 Ki# 58 colesevelam HCl 58 Study Evaluating 58 gastrointestinal stromal tumor GIST 58 refractory cutaneous T 58 pegylated liposomal doxorubicin 58 metastatic castration resistant 58 irinotecan containing 58 PEGINTRON TM 58 creatinine ratio 58 glomerular filtration rate 58 rituximab refractory 58 Hodgkin lymphoma HL 58 aspartate aminotransferase 58 T1DM 58 BRIM3 58 biliary tract cancer 58 ductal carcinomas 58 ImmuKnow assay 58 pT3 58 metastatic hormone refractory 58 International Prognostic Scoring 58 oral antidiabetic medication 58 Fludara 58 Mg Usa 58 TRANSFORMS 58 TOP2A 58 HIV RNA 58 leukemia APL 58 coronary stenosis 58 mg qd 58 abnormal cytology 58 histopathological 58 QTc prolongation 58 daily Infergen 58 Prospective Randomized Trial 58 ORENCIA ® 58 CHOP chemotherapy 58 p# biomarker 58 receiving INTRON 58 zonisamide SR 58 pharmacokinetic PK profile 58 cisplatin vinorelbine 58 decitabine 58 histopathologic findings 58 relapsed refractory multiple myeloma 58 anthracycline taxane 58 oral glucose tolerance 58 perioperative mortality 58 Myelofibrosis 58 5-FU/LV 58 perioperative complications 58 recurrent genital herpes 58 bladder carcinoma 58 HLA DR2 58 carotid intima media 58 confidence intervals CIs 58 malignant fibrous histiocytoma 58 Cardiorespiratory fitness 58 asymptomatic carotid stenosis 58 HuMax EGFr 58 Genotypes 58 androgen ablation 58 Operative mortality 58 KRAS mutation 58 Xanafide 58 doxorubicin docetaxel 58 Tiotropium 58 q#h 58 prospective multicentre 58 miRview squamous 58 Fludarabine 58 pharmacodynamic effects 58 prucalopride 58 Randomized Controlled 58 timepoints 58 pulmonary exacerbation 58 Cystatin C 58 HAQ DI 58 recurrent malignant glioma 58 pulmonary exacerbations 58 hemodynamic variables 58 response pCR 58 peginterferon alfa 58 adefovir treated 58 Safinamide 58 tPSA 58 mitomycin C 58 brivaracetam 58 promoter methylation 58 cytologic 58 Negative Syndrome 58 proteinuria 58 biologic DMARD 58 Unified Parkinson Disease 58 cell lymphoma CTCL 58 eplerenone 58 Relapsing remitting MS 58 glycosylated hemoglobin HbA1c 58 acute GvHD 58 Phase 2b Clinical Trial 58 Adenomas 58 mRNA expression 58 seminoma 58 adalimumab Humira 58 reinfarction 58 qRT PCR 58 #mg/m# [001] 58 mg kg cohorts 58 evaluating tivozanib 58 Median survival 58 evaluating REVLIMID 58 meta regression 58 oblimersen 58 intravesical therapy 58 SGPT 58 neutrophil counts 58 epoetin alpha 58 microalbuminuria 58 R# #mg BID 58 Genes Predict 58 intima media thickness 58 Adalimumab 58 Lenalidomide 58 prospectively randomized 58 ABVD 58 multicenter randomized controlled 58 DLTs 58 mg m² 58 D dimer 58 aplastic anemia AA 58 CK MB 58 ovarian carcinoma 58 platinum refractory 58 alemtuzumab treated